Ozempic competitors show there’s much to gain in weight loss drugs
Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment.
Ozempic’s PBS push could shake up ASX food stocks, and here’s how
Novo Nordisk and Eli Lilly, the companies behind Ozempic, Wegovy, and Mounjaro, have made a request to the Australian government.
More Americans on Ozempic go BLIND as doctors sound alarm over startling side effect
Experts from five states have sounded the alarm about blockbuster weight loss drugs like Ozempic leaving users blind, ...
Is Novo Nordisk's Bottom Here? Oversold Status Below 10Y P/E Lows
Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...
Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business
Telehealth company Hims Hers is pushing the boundaries of drug compounding and testing the limits of regulators.
Trump is unlikely to end Medicare drug price talks — here's what that means for patients and pharma
Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...